Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by DONOVAN, S.
Right arrow Articles by SCOTT, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DONOVAN, S.
Right arrow Articles by SCOTT, D. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1990 British Society for Rheumatology

other

TOLERABILITY OF ENTERIC-COATED SULPHASALAZINE IN RHEUMATOID ARTHRITIS: RESULTS OF A CO-OPERATING CLINICS STUDY

S. DONOVAN*, S. HAWLEY*, J. MACCARTHY* and D. L. SCOTT{dagger}

*Pharmaceutical Division, Pharmacia Ltd UK
{dagger}St Bartholomew's and Homerton Hospitals London

Correspondence to: Correspondence to J. MacCarthy, Pharmacia Ltd, Pharmacia House, Midsummer Boulevard, Milton Keynes MK9 3HP

One thousand three hundred and eighty-two patients with rheumatoid arthritis requiring second-line therapy at 108 centres were entered into an open 6-months prospective tolerability study of enteric-coated sulphasalazine 2 g/day (Salazopyrin EN-tabs). Clinical and laboratory variables were measured, any adverse reactions and the reasons for withdrawal of medication were recorded. The outcome of therapy was known in 87.5% of patients entered of whom 65% continued with sulphasalazine beyond the 6-month study period. 3.2% withdrew for reasons unrelated to treatment, 5% for lack of effect and 26.8% due to an adverse event: gastrointestinal/central nervous 66.6%, rash 15.4%, haematological 5.1%, hepatic 4.7% and miscellaneous 8.1%. 1.2% of patients experienced potentially serious reactions: anaphylactic, haematological and hepatic. The majority of adverse events occurred early and were reversible upon cessation of medication. No clear relationship between withdrawal due to an adverse event attributed to sulphasalazine and the nature of the concomitant non-steroidal anti-inflammatory drug was identified

KEY WORDS: Second-line treatments, Side-effects, Gastrointestinal, Rash, Nervous system, Liver, Haematology, Anaph-ylaxis, Inflammatory bowel disease


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
D L Scott, J S Smolen, J R Kalden, L B A van de Putte, A Larsen, T K Kvien, M Schattenkirchner, P Nash, C Oed, and I Loew-Friedrich
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine
Ann Rheum Dis, October 1, 2001; 60(10): 913 - 923.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
S D Hearing, S Playfor, and S J Bentley
Drug points: High fever induced by sulphasalazine
BMJ, January 28, 1995; 311(7014): 1204b - 1204.
[Full Text]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.